| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/06/2005 | CN1195843C Solid culture method of antrodia camphorate, its cultured solid substance, and its product and application |
| 04/06/2005 | CN1195788C Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| 04/06/2005 | CN1195773C Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 04/06/2005 | CN1195769C Natural antitumor or antiviral substances and use of the same |
| 04/06/2005 | CN1195768C 3'-substd. nucleoside derivs. |
| 04/06/2005 | CN1195766C Thermosensitive cyclotriphosphazene-platinum complex conjugate, its preparation method and anticancer agent containing the same |
| 04/06/2005 | CN1195758C Optical pure analog of camptothecine |
| 04/06/2005 | CN1195757C Optically pure camptothecin analogues |
| 04/06/2005 | CN1195755C Pyrrolo [2, 3-d] pyrimidine compounds |
| 04/06/2005 | CN1195754C Phenanthroline-7-one derivs. and their therapeutic applications |
| 04/06/2005 | CN1195745C Antiviral macrocyclic compounds |
| 04/06/2005 | CN1195740C Pharmaceutical compositions comprising 2-quinolones |
| 04/06/2005 | CN1195735C Sulfonylamino derivatives which inhibit matrix-degrading metallopr teinases |
| 04/06/2005 | CN1195549C Stable amorphous amifostine compositions and methods for the preparation and use of same |
| 04/06/2005 | CN1195548C Stable mitoxantron solutions |
| 04/06/2005 | CN1195534C Physiologically active compositions of basidiomycotina and araliaceae extracts |
| 04/06/2005 | CN1195529C Composition containing muscle-derived active agents |
| 04/06/2005 | CN1195527C Hydroypropyl-beta-cyclodextrin inclusion compound of Rhizoma Zedoariae oil and preparation and preparing method |
| 04/06/2005 | CN1195525C Antitumor agents comprising silicon and nitrogen containing compounds as the principal agent |
| 04/06/2005 | CN1195515C Amide derivatives for antiangiogenic and/or antitumorgenic use |
| 04/06/2005 | CN1195514C Metabolites of ecteinascidin 743 |
| 04/06/2005 | CN1195513C Tocopherols, tocotrienols, other chroman and side chain derivatives and uses |
| 04/06/2005 | CN1195495C Emulsion preconcentrate containing cyclosporin or macrolide |
| 04/05/2005 | US6875886 Modified PSMA ligands and uses related thereto |
| 04/05/2005 | US6875846 Heterologous polypeptide of the TNF family |
| 04/05/2005 | US6875844 Recombinant or chemically synthesized intestinal carboxyesterase (ICE)amino acid sequences for treating solid tumors |
| 04/05/2005 | US6875789 Pyrazole-derived kinase inhibitors and uses thereof |
| 04/05/2005 | US6875780 Compounds that modulate PPAR activity and methods for their preparation |
| 04/05/2005 | US6875779 Cyclooxygenase inhibitor |
| 04/05/2005 | US6875777 Compounds |
| 04/05/2005 | US6875767 (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors |
| 04/05/2005 | US6875757 LPA receptor agonists and antagonists and methods of use |
| 04/05/2005 | US6875745 Synergistic mixture of lapachone and taxane; anticancer, antitumor agents |
| 04/05/2005 | US6875737 Multivalent compounds for crosslinking receptors and uses thereof |
| 04/05/2005 | US6875736 Methods for identifying RNA binding compounds |
| 04/05/2005 | US6875612 Expression vector coding proteins for use in the treatment of tumors |
| 04/05/2005 | US6875599 Enzymatic protein for use in the treatment of inflammation, cancers, cardiovascular, brain, respiratory and crohn's disease |
| 04/05/2005 | US6875570 Proteins and nucleic acids encoding same |
| 04/05/2005 | US6875451 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 04/05/2005 | US6875435 In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent |
| 04/05/2005 | US6875429 Transferring cancer cells to noncancer tumor; injecting into animal |
| 04/05/2005 | CA2226671C 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors |
| 04/05/2005 | CA1341478C Therapeutic methods using catalytic antibodies |
| 03/31/2005 | WO2005028515A1 Recombinant antibody against human insulin-like growth factor |
| 03/31/2005 | WO2005028513A2 High-yield method for the production of human antibodies blocking the biological activity of a human cytokine |
| 03/31/2005 | WO2005028492A1 CRYSTALLINE COMPOUND OF 4'-DEMETHYL-4'-PHOSPHATE-2',3'-BISPENTAFLUOROPHENOXYACETYL-4',6'-ETHYLIDENE-β-D-EPIPODOPHYLLOTOXIN GLUCOSIDE EITHER IN ITS FREE FORM OR SOLVATED WITH ETHANOL |
| 03/31/2005 | WO2005028476A1 Substituted indolizine 1,2,3,6,7,8 derivatives, fgfs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives |
| 03/31/2005 | WO2005028470A1 Quinazoline derivatives |
| 03/31/2005 | WO2005028469A1 Quinazoline derivatives |
| 03/31/2005 | WO2005028444A1 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases |
| 03/31/2005 | WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
| 03/31/2005 | WO2005027973A2 Combinations of a vegf receptor inhibitor with other therapeutic agents |
| 03/31/2005 | WO2005027971A1 Treatment of gastrointestinal stromal tumors with imatinib and midostaurin |
| 03/31/2005 | WO2005027970A1 Drugs for treating cancer |
| 03/31/2005 | WO2005027966A2 Antibodies with altered effector functions |
| 03/31/2005 | WO2005027965A1 Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis. |
| 03/31/2005 | WO2005027952A1 Composition exerting physiological activity via biological immune mechanism |
| 03/31/2005 | WO2005027951A1 Method for controlling angiogenesis in animals |
| 03/31/2005 | WO2005027942A1 Pharmaceutical active ingredient made from snake poison to fight against melanomas |
| 03/31/2005 | WO2005027938A1 Chemotherapeutic antineoplastic treatment |
| 03/31/2005 | WO2005027937A1 Glycolipid-containing composition, use thereof and process for producing the same |
| 03/31/2005 | WO2005027936A2 Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans |
| 03/31/2005 | WO2005027931A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
| 03/31/2005 | WO2005027930A1 2-alkylene-19-nor-vitamin d derivatives for the treatment of osteosarcoma |
| 03/31/2005 | WO2005027929A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen |
| 03/31/2005 | WO2005027926A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bone morphogenetic protein |
| 03/31/2005 | WO2005027924A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
| 03/31/2005 | WO2005027921A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
| 03/31/2005 | WO2005027918A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor |
| 03/31/2005 | WO2005027916A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors |
| 03/31/2005 | WO2005027915A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone |
| 03/31/2005 | WO2005027913A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| 03/31/2005 | WO2005027910A1 Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias |
| 03/31/2005 | WO2005027907A1 Use of chk1 inhibitors to control cell proliferation |
| 03/31/2005 | WO2005027899A1 Use of fumaric acid derivatives for the prophylaxis and treatment of genome damage |
| 03/31/2005 | WO2005027893A1 HUMAN β-DEFENSIN SECRETION PROMOTER |
| 03/31/2005 | WO2005027888A1 Use of the effective constituents from rhubarb for the manufacture of a medicament for the enhancement of as2 o3 induced apoptosis |
| 03/31/2005 | WO2005027831A2 Modulators of p-selectin glycoprotein ligand 1 |
| 03/31/2005 | WO2005027830A2 Chimeric transcription factor decoy oligonucleotides |
| 03/31/2005 | WO2005019193A3 Phenylurea derivatives useful in the treatment of conditions mediated by polo-like kinases (plk) |
| 03/31/2005 | WO2005009961A3 Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| 03/31/2005 | WO2005009947A3 Aryl heteroaromatic products, compositions comprising the same and use thereof |
| 03/31/2005 | WO2005005632A3 SMALL INTERFERING RNA SPECIFIC TO SUB-UNITS $G(A), $G(A)' AND $G(B) OF THE KINASE PROTEIN CK2, AND THE APPLICATIONS OF THE SAME |
| 03/31/2005 | WO2004110490A3 Use of vegf inhibitors for tumor regression |
| 03/31/2005 | WO2004101780A3 Heparanase-derived peptides for vaccination of tumor patients |
| 03/31/2005 | WO2004096212A9 Pyrazole compounds as hsp90 inhibitors for the treatment of cancer |
| 03/31/2005 | WO2004092139A3 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| 03/31/2005 | WO2004037161A3 Cyclic prodrugs of pmea one of its analogues |
| 03/31/2005 | WO2004010951A8 Method of treating tumors |
| 03/31/2005 | WO2003063897A8 Method of providing prophylaxis for tuberculosis in hiv positive individuals |
| 03/31/2005 | WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 03/31/2005 | WO2003018756A3 Methods for preparing purified prostaglandin e synthase |
| 03/31/2005 | WO2002099054A3 Hccss as modifiers of the p53 pathway and methods of use |
| 03/31/2005 | WO2002067968A9 14-3-3 binding molecules as sensitizers for anticancer therapies |
| 03/31/2005 | WO2002042319A9 2-substituted estrogens as antiangiogenic agents |
| 03/31/2005 | US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents |
| 03/31/2005 | US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease |
| 03/31/2005 | US20050070706 Antidiabetic agents; obesity; controlling appetite |
| 03/31/2005 | US20050070694 Antagonistic anti-htnfsf13b human antibodies |
| 03/31/2005 | US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders |